Literature DB >> 14511349

Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism.

Laura Wiseman Harris1, Trevor Sharp, Jane Gartlon, Declan N C Jones, Paul J Harrison.   

Abstract

Brief N-methyl-D-aspartate (NMDA) receptor blockade in neonatal rats has been reported to increase neuronal apoptosis. We replicated this finding using MK-801 (0.5 mg/kg) administered twice on postnatal day 7, and then studied the long-term consequences. In adulthood, treated rats showed reduced volume and neuronal number within the hippocampus, and altered hippocampal NMDA receptor (NR1 subunit) expression. Synaptophysin mRNA was decreased in the thalamus (laterodorsal nucleus). Adult MK-801-treated females had prepulse inhibition deficits and increased locomotor activity. The data show that a transient and limited glutamatergic intervention during development can have chronic behavioural, structural and molecular effects. The effects are reminiscent of alterations reported in schizophrenia and, as such, are consistent with hypotheses advocating a role for NMDA receptor hypofunction, and aberrant apoptosis, in the neurodevelopmental pathogenesis of the disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511349     DOI: 10.1046/j.1460-9568.2003.02902.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  59 in total

1.  In utero PCP exposure alters oligodendrocyte differentiation and myelination in developing rat frontal cortex.

Authors:  Josette S Lindahl; Barton R Kjellsen; Jamie Tigert; Robin Miskimins
Journal:  Brain Res       Date:  2008-07-15       Impact factor: 3.252

2.  Neonatal exposure to MK801 promotes prepulse-induced delay in startle response time in adult rats.

Authors:  Amanda Lyall; John Swanson; Chun Liu; Terry D Blumenthal; Christopher Paul Turner
Journal:  Exp Brain Res       Date:  2009-06-30       Impact factor: 1.972

3.  NMDA receptor involvement in spatial delayed alternation in developing rats.

Authors:  Deborah J Watson; Mariel R Herbert; Mark E Stanton
Journal:  Behav Neurosci       Date:  2009-02       Impact factor: 1.912

4.  Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.

Authors:  Masoumeh Nozari; Mohammad Shabani; Mahdieh Hadadi; Nafiseh Atapour
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

5.  Impaired social behaviors and minimized oxytocin signaling of the adult mice deficient in the N-methyl-d-aspartate receptor GluN3A subunit.

Authors:  Jin Hwan Lee; James Ya Zhang; Zheng Zachory Wei; Shan Ping Yu
Journal:  Exp Neurol       Date:  2018-03-16       Impact factor: 5.330

6.  Neonatal PCP is more potent than ketamine at modifying preweaning behaviors of Sprague-Dawley rats.

Authors:  Sherin Y Boctor; Cheng Wang; Sherry A Ferguson
Journal:  Toxicol Sci       Date:  2008-07-30       Impact factor: 4.849

Review 7.  Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Authors:  Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff
Journal:  Psychopharmacology (Berl)       Date:  2008-06-21       Impact factor: 4.530

8.  Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice.

Authors:  Linnéa Asp; Maria Holtze; Susan B Powell; Håkan Karlsson; Sophie Erhardt
Journal:  Int J Neuropsychopharmacol       Date:  2009-07-17       Impact factor: 5.176

9.  Long-lasting behavioral effects in neonatal mice with multiple exposures to ketamine-xylazine anesthesia.

Authors:  Lianyan Huang; Scott Hayes; Guang Yang
Journal:  Neurotoxicol Teratol       Date:  2016-09-10       Impact factor: 3.763

10.  Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration.

Authors:  Chunmei Guo; Yang Yang; Yun'ai Su; Tianmei Si
Journal:  J Biomed Biotechnol       Date:  2010-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.